Glaxosmithkline Pharmaceutical share price
You have to be logged in to add this to Watchlist.- ₹2,805.75(-0.77%)May 19, 2025 15:29:26 PM IST
- NSE
- BSE
- Vol : 102.23K (NSE + BSE)Last 20 day avg : 272.76 K
Glaxosmithkline Pharmaceutical is trading -0.77% lower at Rs 2,805.75 as compared to its last closing price. Glaxosmithkline Pharmaceutical has been trading in the price range of 2,860.00 & 2,800.00. Glaxosmithkline Pharmaceutical has given 25.61% in this year & 2.49% in the last 5 days. Glaxosmithkline Pharmaceutical has TTM P/E ratio 52.83 as compared to the sector P/E of 24.50.There are 4 analysts who have initiated coverage on Glaxosmithkline Pharmaceutical. There are 1 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 1 analysts have given the stock a sell rating.The company posted a net profit of 262.87 Crores in its last quarter.Listed peers of Glaxosmithkline Pharmaceutical include Abbott India (0.29%), Alkem Laboratories (2.05%), Glaxosmithkline Pharmaceutical (-0.77%).The Mutual Fund holding in Glaxosmithkline Pharmaceutical was at 5.17% in 31 Mar 2025. The MF holding has increased from the last quarter. The FII holding in Glaxosmithkline Pharmaceutical was at 4.52% in 31 Mar 2025. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on May 19, 2025, 02:18 PM UTC
- Dividend YieldHigher than industry1.48Annual dividends as a percentage of the stock price.
- P/BHigher than historical values24.56The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/ELower than historical values51.88Price-to-earnings ratio based on trailing 12-month earnings
- BetaLow volatility0.22Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityLower than industry0.01The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in March quarter by 4.79% from Rs 974.37 crore to Rs 929.80 crore, year-on-year
- The company has grown its March quarter profit by 35.16% from Rs 194.48 crore to Rs 262.87 crore, year-on-year
- The debt to equity of the company is lower than the industry median
- Company can comfortably pay off its interest obligations with its earnings
- R1
- 3,103.20
- R2
- 3,246.95
- R3
- 3,448.90
- S1
- 2,757.50
- S2
- 2,555.55
- S3
- 2,411.80
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Abbott India | Bullish | 30,650.00 | 0.29 | 65,325.27 | 45.91 | 15.34 | 1.55 | 3.73 |
| Alkem Laboratories | Moderately Bullish | 5,328.05 | 2.05 | 63,704.83 | 34.71 | 6.05 | 0.80 | 2.22 |
| Glaxosmithkline Pharmaceutical | Neutral | 2,805.75 | -0.77 | 47,640.33 | 51.85 | 24.56 | 1.48 | 0.13 |
| Glenmark Pharmaceuticals | Neutral | 1,438.50 | -0.61 | 40,594.59 | - | 5.21 | 0.17 | 1.93 |
| Biocon | Neutral | 341.50 | 0.59 | 41,000.49 | 43.24 | 1.88 | 0.15 | 59.81 |
- Promoter(s) holds a high stake in the company at 75.00%
- FIIs are invested in this company
- FIIs holding has increased by 0.02 percentage points from previous quarter
- Mutual Funds holding has increased by 0.21 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-05-13 | Audited Results & Final Dividend |
| 2025-02-14 | Quarterly Results |
| 2025-02-10 | Quarterly Results |
| 2024-10-29 | Quarterly Results & Interim Dividend |
| 2024-08-02 | Quarterly Results |
- IndustryBiotechnology & Drugs
- ISININE159A01016
- BSE Code500660
- NSE CodeGLAXO
Glaxosmithkline Pharmaceutical is trading at 2805.75 as on Mon May 19 2025 09:59:26. This is -0.77% lower as compared to its previous closing price of 2827.60.
The market capitalization of Glaxosmithkline Pharmaceutical is 47640.33 Cr as on Mon May 19 2025 09:59:26.
The average broker rating on Glaxosmithkline Pharmaceutical is Buy. The breakup of analyst rating is given below -
- 1 analysts have given a strong buy rating
- 1 analysts have given a buy rating
- 1 analysts have given a hold rating
- 1 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Glaxosmithkline Pharmaceutical is 3147.45 whereas the 52 wk low is 1924.30
Glaxosmithkline Pharmaceutical can be analyzed on the following key metrics -
- TTM P/E: 52.83
- Sector P/E: 24.50
- Dividend Yield: 1.48%
- D/E ratio: 0.01
Glaxosmithkline Pharmaceutical reported a net profit of 927.58 Cr in 2025.
The Mutual Fund Shareholding was 5.17% at the end of 31 Mar 2025.